<DOC>
	<DOC>NCT00973271</DOC>
	<brief_summary>The hypothesis of this study is that DCCR is effective as both monotherapy and in combination with a statin in lowering triglycerides in subjects with very high triglycerides</brief_summary>
	<brief_title>Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides</brief_title>
	<detailed_description>Very high triglyceride is a risk for pancreatitis. Studies have shown Diazoxide Choline has the potential to effectively lower triglycerides in patients with very high triglycerides.</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Fenofibric acid</mesh_term>
	<mesh_term>Choline</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Diazoxide</mesh_term>
	<criteria>INCLUSION CRITERIA: Fasting triglycerides Difference between Visit 3 (7 days prior to Baseline Visit) and Visit 4 (3 days prior to Baseline Visit) ≤ 60% (compared to the higher value of Visit 3 or Visit 4) Runin Triglycerides* ≥ 500 mg/dL and &lt; 1500 mg/dL *Runin Triglyceride is defined as the average fasting triglycerides for Visit 3 (7 days prior to Baseline Visit) and Visit 4 (3 days prior to Baseline Visit). Statin use Either Statinnaive Must not be on statin at Screening and remaining as such during the Runin/Washout Period and throughout the study Or Statintreated Must be receiving a stable and effective dose of statin for ≥ 3 months without significant side effects or intolerance prior to Screening Must be willing to switch to 20 mg atorvastatin at the start of the Runin/Washout Period and continue throughout the study Medication washout All subjects must be willing to undergo washout of all other lipidlowering medications Fasting LDL cholesterol ≤ l60 mg/dL at both Screening Visit and Visit 4 Glycemic status Fasting glucose &lt; 126 mg/dL at Screening Visit HbA1c &lt; 6.5% at Screening Visit EXCLUSION CRITERIA: Medications: recent, current, anticipated Administration of investigational drugs within 1 month prior to Screening Visit Thyroid hormones or preparations within 1 month prior to Screening Visit (except in subjects on stable dose of replacement therapy for at least 1 month) Thiazide diuretics within 2 weeks prior to Screening Visit Discontinuation of betablockers within 1 month prior to Screening Visit or planned discontinuation of betablocker therapy Anticipated requirement for use of prohibited concomitant medications History of allergic reaction or significant intolerance to: Diazoxide Thiazides Sulfonamides Fenofibrate or fenofibric acid derivatives Lifestyle changes • Subjects intending to change exercise habits, quit smoking and/or quit alcohol use during the initial 12week PlaceboControlled Treatment Period of the study Specific diagnoses, medical conditions and history Known type I or III hyperlipidemia Known type 1 DM Known type 2 DM Any other clinically significant endocrine, cardiovascular, pulmonary, neurological, psychiatric, hepatic, gastrointestinal, hematological, renal, or dermatological disease interfering with the assessments of the study medications, according to the Investigator Specific laboratory test results • Any relevant biochemical abnormality interfering with the assessments of the study medications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>hypertriglyceridemia</keyword>
</DOC>